This inhaled-glutathione study did not meet its predetermined primary lung-function target. Later discussion of selected groups and visits should not remove that result. Primary trial
Findings in context
Fifty-four adults and 51 pediatric patients with cystic fibrosis were randomized in a single-blind, year-long placebo-controlled trial. The predetermined 15% improvement target for FEV1% was not achieved. The authors reported selected earlier-visit improvements from baseline among patients with moderate lung disease and a walking-test finding in the pediatric population. Registration: NCT01450267. Primary trial
Our appraisal: retain the denominator, visit, and contrast
A finding in a selected subgroup at an earlier visit is not the whole-population primary result at the planned endpoint. It may motivate additional research, but it should keep its subgroup and time labels.
A within-group improvement from baseline is also not automatically superiority over placebo. The relevant comparison and uncertainty must be inspected. For an invented example, both groups could improve during a season of lower symptom burden. Improvement in the active group alone would not isolate an intervention effect.
What a full review should test
We would check whether subgroup and visit analyses were prespecified, how multiplicity was addressed, and whether an interaction test supported differences between populations. We would also inspect the exact definition of FEV1%, the primary target, and how missing measurements were handled.
Age-related subgroups require care because the same physical test may have different baseline distributions and interpretation across ages. A pediatric walking observation should not be silently generalized to all participants.
The study concerns a specified inhaled preparation under clinical supervision. It is not a guide to inhaling a research material, changing a cystic-fibrosis regimen, or substituting one route for another.
Frequently asked questions
Was the predetermined primary target achieved?
No, according to the trial report.
Were adults and children both enrolled?
Yes. The reported sample included both groups.
Do favorable subgroup observations replace the primary result?
No. They belong beside it with their limitations intact.
Does improvement from baseline establish placebo superiority?
No. That is a separate comparison.
Can a finding at month three become a year-long benefit claim?
Not without evidence at the relevant duration.
Does this validate all glutathione formulations?
No. Preparation and route are part of the intervention identity.
What source was reviewed?
The primary indexed abstract and record. Full statistical and safety review remains pending.